News for Viridian Therapeutics, Inc. (VRDN)

Evercore ISI has revised its price target for Viridian Therapeutics (VRDN), reducing it from $41 to $38. Despite this adjustment, the firm maintains an Outperfo

Summary Viridian Therapeutics Inc (VRDN), a biopharmaceutical company dedicated to developing innovative treatments for serious and rare diseases, announced on

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicin

Viridian Therapeutics (VRDN) grants non-qualified stock options for 175,000 shares to a new employee under Nasdaq Listing Rule 5635(c)(4). The stock opt

Viridian Therapeutics has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026. Click here to find out why VRDN stock is a Buy.

Summary Viridian Therapeutics Inc (VRDN), a biopharmaceutical company dedicated to developing best-in-class medicines for serious and rare diseases, announced i

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicin

Viridian Therapeutics (VRDN) to participate in Jefferies and Goldman Sachs Global Healthcare Conferences. Webcasts of the presentations will be availabl

In a recent update, Needham analyst Serge Belanger has maintained a "Buy" rating on Viridian Therapeutics, Inc. (VRDN), while making adjustments to the price ta

Citizens JMP has revised its price target for Viridian Therapeutics (VRDN), lowering it from $42 to $38, while maintaining an Outperform rating on the company's

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines fo

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 8.42% and 55.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireEMERYVILLE, Calif., April 29, 2025 Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD

**media[600316,600317,600318,600319,600320,600321]**

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicin

Viridian Therapeutics Inc's advanced product candidate, veligrotug, targets a clinically validated treatment for thyroid eye disease.VRDN's diversified portfol

Viridian Therapeutics' VRDN-001 demonstrates rapid efficacy in TED. Read why VRDN stock may benefit from FDA approval and market differentiation.

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 22.86% and 17.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?